Table 1

Intracranial aneurysms treated with the pCONus device, clinical and anatomical findings in 21 patients

PatientHunt+HessFisher scoreAneurysm locationNeck widthDome widthDome/neck ratioEndoventricular drainBefore medicationAfter medicationIntraoperative complicationsImmediate postoperative mRRCFirst follow-up (months)Radiographic outcome at delayed follow-up (mRRC)Final mRS
1IVIVBasilar tip7.213.51.87Y—pre-op500 ASA IV, 600 clopidogrel p.o.ClopidogrelNoIIIb2Stable neck remnant (IIIb)1
2VIVAcomA6.18.51.4Y—pre-op2×500 mg ASA IVClopidogrelNoIIIbDeadDead6
3IVIVBasilar tip11.114.41.3Y—pre-op500 ASA IV, 300 clopidogrel p.o.ClopidogrelNoIIIbDeadDead6
4IVIVBasilar tip4.45.11.16Y—pre-op2×500 ASA IV, 600 clopidogrel p.o.ClopidogrelNoIDeadDead6
5IIIVRight MCA10.613.21.24Y—pre-op500 ASA IV, 300 clopidogrel p.o.ClopidogrelNoIIIb2Compaction and growth (IIIb)—re-treatment0
6IVIVAcomA33.21.06Y—pre-op500 ASA IV, 600 clopidogrel p.o.ClopidogrelThrombus in A1I3Complete occlusion (I)0
7IIIIIAcomA4.461.36NASA IV, clopidogrel p.o. and eptifibatide IVClopidogrelNoI6Complete occlusion (I)1
8IIIVBA fenestration9.613.41.4Y—pre-opASA IV, clopidogrel p.o. and eptifibatide IVClopidogrelNoIIDeadDead6
9IIIIVBasilar tip7.811.11.42Y—pre-opASA IV, ticagrelor p.o. and eptifibatide IVBriliqueNoI4Complete occlusion (I)1
10IIIIRight MCA8.511.91.4NASA IV, ticagrelor p.o. and eptifibatide IVBriliqueNoIIIb3Stable neck remnant (IIIb)0
11IIIAcomA6.258.031.28NLoading ASA IV and ticagrelor p.o.BriliqueNoI3Small neck recurrence (II)0
12IIIBasilar tip5.528.21.48NASA IV, ticagrelor p.o. and eptifibatide IVBriliqueNoI3Complete occlusion (I)0
13IIIVBasilar tip5.310.72Y—pre-opASA IV, ticagrelor p.o. and eptifibatide IVBriliqueNoI5Coil compaction + small neck recurrence (II)—re-treatment0
14VIVBasilar tip5.56.31.14Y—pre-opASA IV, ticagrelor p.o. and eptifibatide IVClopidogrelNoI7Complete occlusion (I)0
15IIIIVAcomA5.514.62.65Y—pre-opASA IV, ticagrelor p.o. and eptifibatide IVBriliqueNoIIIa9Complete occlusion (I)2
16IIBasilar tip7.769.21.18NLoading ASA IV and ticagrelor p.o.BriliqueNoIIIb2Complete occlusion (I)2
17IIIIIILeft MCA540.8NASA IV, ticagrelor p.o. and eptifibatide IVBriliqueNoII2Stable neck remnant (II)—re-treatment1
18IIRight MCA33.41.13NASA IV, ticagrelor p.o. and eptifibatide IVBriliqueNoII3Complete occlusion (I)1
19IIAcomA8.514.11.66NASA IV, ticagrelor p.o. and eptifibatide IVBriliquePerforation+thrombusII3Neck recurrence0
20IIAcomA471.75NASA IV, ticagrelor p.o. and eptifibatide IVBriliqueNoI3Complete occlusion (I)0
21IIIIPericallosal6122NASA IV, ticagrelor p.o. and eptifibatide IVAspirin and BriliqueIIIbNone yetNone yetN/A
  • AcomA, anterior communicating artery; ASA, acetylsalicylic acid; BA, Basilar artery; MCA, middle cerebral artery; mRCC, modified Raymond–Roy classification; mRS, modified Rankin Scale